JonesResearch initiated coverage of Bicara Therapeutics (BCAX) with a Buy rating and $22 price target The firm says clinical data from Keytruda combinations with bispecific antibodies of Bicara and Merus (MRUS) showed more than doubling of clinical benefits in head and neck cancer. Bicara’s “differentiated drug profile offers a compelling investment case,” the analyst tells investors in a research note. JonesResearch views the shares as oversold at current levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAX:
- Bicara Therapeutics price target lowered to $40 from $41 at H.C. Wainwright
- Bicara Therapeutics initiated with an Overweight at Piper Sandler
- Bicara Therapeutics Reports Q2 2025 Results and Progress
- Promising Clinical Developments and Financial Stability Drive Buy Rating for Bicara Therapeutics
- Bicara Therapeutics reports Q2 EPS (50c), consensus (54c)